CY1112645T1 - Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275) - Google Patents

Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275)

Info

Publication number
CY1112645T1
CY1112645T1 CY20121100293T CY121100293T CY1112645T1 CY 1112645 T1 CY1112645 T1 CY 1112645T1 CY 20121100293 T CY20121100293 T CY 20121100293T CY 121100293 T CY121100293 T CY 121100293T CY 1112645 T1 CY1112645 T1 CY 1112645T1
Authority
CY
Cyprus
Prior art keywords
benzamide
pyridin
polymorph
aminofynyl
methoxycarbonyl
Prior art date
Application number
CY20121100293T
Other languages
English (en)
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112645(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1112645T1 publication Critical patent/CY1112645T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Περιγράφεται το κρυσταλλικό Πολύμορφο Β του Ν-(2-αμινοφαινυλο)-4-[Ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλαμινομεθυλο] βενζαμιδίου (ΜS-275) του τύπου (Ι) καθώς και η διαδικασία για την παραγωγή της εν λόγω ένωσης και η χρήση της ως φάρμακο για την θεραπεία επιλεγμένων νόσων.
CY20121100293T 2008-08-29 2012-03-20 Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275) CY1112645T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29
EP20090778301 EP2350005B1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (1)

Publication Number Publication Date
CY1112645T1 true CY1112645T1 (el) 2016-02-10

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100293T CY1112645T1 (el) 2008-08-29 2012-03-20 Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275)

Country Status (36)

Country Link
US (2) US7973166B2 (el)
EP (1) EP2350005B1 (el)
JP (1) JP4921616B2 (el)
KR (1) KR101073760B1 (el)
CN (1) CN102137846B (el)
AR (1) AR073226A1 (el)
AT (1) ATE538094T1 (el)
AU (1) AU2009286982C1 (el)
BR (1) BRPI0918580B8 (el)
CA (1) CA2735294C (el)
CO (1) CO6351736A2 (el)
CR (2) CR20110107A (el)
CY (1) CY1112645T1 (el)
DK (1) DK2350005T3 (el)
DO (1) DOP2011000064A (el)
EA (1) EA016811B1 (el)
EC (1) ECSP11010849A (el)
ES (1) ES2378640T3 (el)
HK (1) HK1160107A1 (el)
HN (1) HN2011000609A (el)
HR (1) HRP20120183T8 (el)
IL (1) IL211276A (el)
MA (1) MA32610B1 (el)
MX (1) MX2011002248A (el)
MY (1) MY149058A (el)
NZ (1) NZ591387A (el)
PE (2) PE20110677A1 (el)
PL (1) PL2350005T3 (el)
PT (1) PT2350005E (el)
RS (1) RS52164B (el)
SI (1) SI2350005T1 (el)
SM (1) SMT201200026B (el)
SV (1) SV2011003846A (el)
TW (1) TWI427062B (el)
WO (1) WO2010022988A1 (el)
ZA (1) ZA201102285B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591387A (en) 2008-08-29 2012-03-30 Bayer Pharma AG N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
US11208382B2 (en) 2017-07-28 2021-12-28 Hangzhou Solipharma Co., Ltd. Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
CA3218617A1 (en) 2021-05-10 2022-11-17 Thierry Bonnaud Novel forms of entinostat

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
NZ591387A (en) 2008-08-29 2012-03-30 Bayer Pharma AG N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b

Also Published As

Publication number Publication date
USRE45499E1 (en) 2015-04-28
PL2350005T3 (pl) 2012-05-31
EA016811B1 (ru) 2012-07-30
HRP20120183T8 (en) 2012-11-30
CO6351736A2 (es) 2011-12-20
ATE538094T1 (de) 2012-01-15
WO2010022988A1 (en) 2010-03-04
SV2011003846A (es) 2011-07-27
MA32610B1 (fr) 2011-09-01
AR073226A1 (es) 2010-10-20
US20100056585A1 (en) 2010-03-04
KR101073760B1 (ko) 2011-10-13
TWI427062B (zh) 2014-02-21
SMT201200026B (it) 2012-07-10
US7973166B2 (en) 2011-07-05
HK1160107A1 (en) 2012-08-10
RS52164B (en) 2012-08-31
EP2350005B1 (en) 2011-12-21
BRPI0918580B1 (pt) 2020-11-24
ES2378640T3 (es) 2012-04-16
BRPI0918580B8 (pt) 2021-05-25
KR20110038187A (ko) 2011-04-13
JP4921616B2 (ja) 2012-04-25
BRPI0918580A8 (pt) 2017-07-11
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
CN102137846A (zh) 2011-07-27
SI2350005T1 (sl) 2012-03-30
DOP2011000064A (es) 2011-03-31
EP2350005A1 (en) 2011-08-03
IL211276A0 (en) 2011-04-28
EA201100354A1 (ru) 2011-10-31
CA2735294C (en) 2013-10-15
JP2012500819A (ja) 2012-01-12
HN2011000609A (es) 2014-09-29
CN102137846B (zh) 2014-04-23
ECSP11010849A (es) 2011-03-31
PT2350005E (pt) 2012-03-12
AU2009286982A1 (en) 2010-03-04
IL211276A (en) 2014-07-31
TW201014820A (en) 2010-04-16
HRP20120183T1 (hr) 2012-03-31
AU2009286982B2 (en) 2011-06-23
CR20160465A (es) 2016-12-06
MX2011002248A (es) 2011-03-29
AU2009286982C1 (en) 2012-04-26
NZ591387A (en) 2012-03-30
PE20141062A1 (es) 2014-09-19
CR20110107A (es) 2011-04-28
ZA201102285B (en) 2011-12-28
CA2735294A1 (en) 2010-03-04
BRPI0918580A2 (pt) 2015-12-01
DK2350005T3 (da) 2012-03-19

Similar Documents

Publication Publication Date Title
CY1112645T1 (el) Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275)
CY1119530T1 (el) Συνθεσεις και μεθοδοι ρυθμισης toy fxr
CY1119119T1 (el) Κρυσταλλικες μορφες 6-[2-(μεθυλκαρβαμοϋλ)φαινυλσουλφανυλ]-3-ε-[2-(πυριδιν-2-υλ)αιθενυλ]ινδαζολιου καταλληλες για τη θεραπεια μη κανονικης αναπτυξης κυτταρου σε θηλαστικα
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
TW201612158A (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
CY1113177T1 (el) Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201290416A1 (ru) Новые спиропиперидиновые соединения
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
CY1112670T1 (el) Παραγωγα του 5.6-bisaryl-2-πυριδιν-καρβοξαμιδιου, η παρασκευη τους και η εφαρμογη τους σε θεραπευτικη αγωγη ως ανταγωνιστες των υποδοχεων στην ουροτενσινη ii
EA200900797A1 (ru) Способ синтеза производных 3-аминотетрагидрофуран-3-карбоновой кислоты и их применение в качестве лекарственных средств
EA201270816A1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso